title: [Chronic experimentation with TRH administered intramuscularly in spinocerebellar degeneration. Double-blind cross-over study in 30 subjects].
abstract: Thyrotropin-releasing hormone (TRH) has been reported to improve the clinical picture of patients with the predominantly cerebellar form of spinocerebellar degeneration. The authors performed a double-blind, double cross-over, four-month trial, where TRH, at the daily dose of 2 and 4 mg, and placebo were given intramuscularly over a period of one month each. Sixteen patients with Friedreich's disease and 14 patients with different forms of spinocerebellar degeneration completed the trial. Features of cerebellar involvement, such as dysarthria, dysmetria and stance ataxia, showed a slight but significant improvement during TRH treatment. TRH was well tolerated. Transient nausea was the most frequent side-effect.
authors.affiliation: Clinica Neurologica, II Facoltà di Medicina, Università, Napoli.
authors.forename: A
authors.initials: A
authors.lastname: Filla
authors.forename: G
authors.initials: G
authors.lastname: De Michele
authors.forename: L
authors.initials: L
authors.lastname: Di Martino
authors.forename: A
authors.initials: A
authors.lastname: Mengano
authors.forename: L
authors.initials: L
authors.lastname: Iorio
authors.forename: M A
authors.initials: MA
authors.lastname: Maggio
authors.forename: G
authors.initials: G
authors.lastname: Campanella
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D005621:Friedreich Ataxia / Q000188:drug therapy; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D013132:Spinocerebellar Degenerations / Q000188:drug therapy*; D013973:Thyrotropin-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D013973:Thyrotropin-Releasing Hormone
vernacular_title: Sperimentazione cronica del TRH per via intramuscolare nelle degenerazioni spino-cerebellari. Studio in doppio cieco cross-over su 30 soggetti.